Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880,a VEGFRR and MET kinase inhibitor, administered daily to patients with advanced malignancies [abstract]

Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880,a VEGFRR and MET kinase inhibitor, administered daily to patients with advanced malignancies [abstract]. Proc AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2007; A-B248.


© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.